{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BMRN/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"BMRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMRN\",,,,,undefined,":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"Biomarin Pharmaceutical","latestPrice":59.17,"timestamp":1744920000000,"preClose":58.82,"halted":0,"volume":1247162,"hourTrading":{"tag":"盘后","latestPrice":59.17,"preClose":59.17,"latestTime":"17:18 EDT","volume":102473,"amount":6063332.84,"timestamp":1744924699909},"delay":0,"floatShares":179368327,"shares":191754170,"eps":2.207261,"marketStatus":"Market Closed","change":0.35,"latestTime":"04-17 16:00:00 EDT","open":58.44,"high":59.62,"low":58,"amount":73777664.02328001,"amplitude":0.027542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.207261,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":58.82,"preHourTrading":{"tag":"盘前","latestPrice":58.56,"preClose":58.82,"latestTime":"09:29 EDT","volume":472,"amount":27643.230352000002,"timestamp":1744896599999},"postHourTrading":{"tag":"盘后","latestPrice":59.17,"preClose":59.17,"latestTime":"17:18 EDT","volume":102473,"amount":6063332.84,"timestamp":1744924699909},"volumeRatio":0.659425538850371,"impliedVol":0.4459,"impliedVolPercentile":0.9522},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMRN\",,,,,undefined,":{"symbol":"BMRN","floatShares":179368327,"roa":"5.15%","roe":"8.05%","lyrEps":2.246307,"volumeRatio":0.659425538850371,"shares":191754170,"dividePrice":0,"high":59.62,"amplitude":0.027542,"preClose":58.82,"low":58,"week52Low":52.93,"pbRate":"2.01","psRate":"3.98","week52High":94.85,"institutionHeld":0.9275,"latestPrice":59.17,"eps":2.207261,"divideRate":0,"volume":1247162,"delay":0,"ttmEps":2.207261,"open":58.44,"prevYearClose":65.73,"prevWeekClose":56.82,"prevMonthClose":70.69,"prevQuarterClose":70.69,"fiveDayClose":56.32,"twentyDayClose":71.6,"sixtyDayClose":62.02,"earningDate":1746028800000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMRN\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509801725","title":"DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2509801725","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509801725?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:54","pubTimestamp":1738940040,"startTime":"0","endTime":"0","summary":"Denali TherapeuticsDNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa , in 47 patients with Hunter syndrome  over a 24-week treatment period, along with additional long-term follow-up data. DNLI’s wholly-owned program, tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase replacement therapy in development for MPS II.Per the additional long-term data readout from the phase I/II study, treatment with tividenofusp alfa resulted in significant and substantial reductions in key disease biomarkers within the central nervous system and peripheral system, bringing them to normal or near-normal levels. Such biomarkers included cerebrospinal fluid and urine heparan sulfate, as well as neurofilament light, a recognized marker of neurodegeneration.Per Denali, such efficacy data suggests the pervasive nature of treatment effects in MPS II patients over the longer term.Shares of DNLI have plunged 28.1% in the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dnli-reports-upbeat-longer-term-145400778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALNY","CSTL","BK4585","DNLI","BK4196","BMRN","IE00B19Z3581.USD","BK4548","BK4588","BK4139","BK4566","BK4535","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE0002270589.USD"],"gpt_icon":0},{"id":"2509209101","title":"RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509209101","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509209101?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:35","pubTimestamp":1738856100,"startTime":"0","endTime":"0","summary":"Shares of Rezolute RZLT have rallied 30.8% in the past six months against the industry’s decline of 4.1%, driven by investor enthusiasm about the company’s encouraging progress with the development activities for its lead pipeline candidate, ersodetug .Rezolute is a late-stage clinical biotech focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism .The company is evaluating ersodetug in the phase III sunRIZE study for treating patients with congenital HI, an ultra-rare pediatric genetic disorder.An independent Data Monitoring Committee  reviewed the OLA of the sunRIZE study, which evaluated ersodetug in eight infants aged between three months to one year for treating congenital HI. Per the DMC review, treatment with ersodetug was generally safe and well-tolerated in the given patient population. The DMC also approved the enrollment of subsequent infants into the double-blind portion of the study.Some better-ranked stocks in the biotech sector are Harm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rzlt-shares-rise-30-8-153500425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4139","BK4007","BK4196","HRMY","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B19Z3581.USD","HI","IE00B7SZLL34.SGD","LU2360032135.SGD","LU0029874061.USD","BK4566","BK4161","BMRN","RZLT","LU0128526141.USD","LU2125154778.USD","LU2125154935.USD"],"gpt_icon":0},{"id":"2509209176","title":"GHRS Stock Rallies 55% in a Week: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2509209176","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509209176?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:25","pubTimestamp":1738855500,"startTime":"0","endTime":"0","summary":"Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the primary goal in a mid-stage study of its investigational, inhalable mebufotenin product candidate, GH001, to treat patients with treatment-resistant depression .Per the data readout from the phase IIb TRD study, 40 patients treated with GH001 achieved a significant 15.2-point reduction in Montgomery-sberg Depression Rating Scale  score by Day 8, while the placebo group, comprising 41 patients, showed a slight increase of 0.3 points. Please note that MADRS is a metric showing the improvement of depressive symptoms in patients compared with placebo after the treatment period.It was observed that most patients receiving GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group. Furthermore, in the open-label extension  portion of the phase IIb study, TRD patients who had remission on Day 8 after their first dosage had a 91.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ghrs-stock-rallies-55-week-152500374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00B19Z3581.USD","BK4539","BK4196","IE0002270589.USD","BK4588","CSTL","IE00B7SZLL34.SGD","ALNY","BK4007","BMRN","BK4566","BK4548","IE00B19Z3B42.SGD","GHRS","BK4585"],"gpt_icon":0},{"id":"2509253947","title":"3 Reasons Growth Investors Will Love BioMarin (BMRN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509253947","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509253947?lang=en_us&edition=fundamental","pubTime":"2025-02-06 01:45","pubTimestamp":1738777506,"startTime":"0","endTime":"0","summary":"Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score , which looks beyond the traditional growth attributes to analyze a company's real growth prospects.BioMarin Pharmaceutical  is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-reasons-growth-investors-love-174506327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","ISBC","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","BK4139","IE0002270589.USD","BK4566","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2509281247","title":"BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2509281247","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509281247?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:00","pubTimestamp":1738764000,"startTime":"0","endTime":"0","summary":"SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc.  today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.Dial-in NumberU.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 1878833. U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playback ID: 1878833. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biomarin-host-fourth-quarter-full-140000822.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomarin-host-fourth-quarter-full-140000822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","BK4181","BK4561","BK4144","IE00B19Z3581.USD","HST","BK4590","IE0002270589.USD","IE00B19Z3B42.SGD","BK4218","BK4581","BK4588","ET","BMRN","BK4139","BK4566","BK4585"],"gpt_icon":0},{"id":"2509644462","title":"CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2509644462","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509644462?lang=en_us&edition=fundamental","pubTime":"2025-02-05 00:07","pubTimestamp":1738685220,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  rendered a positive opinion for the expanded use of the subcutaneous  formulation of Rybrevant  in advanced EGFR-mutated non-small cell lung cancer .The CHMP recommendation is for SC Rybrevant in combination with Lazcluze  for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion  or L858R mutation. The CHMP also recommended marketing authorization for the SC formulation of Rybrevant as a monotherapy for treating adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy.The European Commission had approved a combination of its intravenously administered Rybrevant plus Lazcluze for a similar use in Europe in December 2024.In the past year, shares of J&J have lost 2.5% compared with the industry’s decline of 2.6%.CHMP Nod to JNJ's Rybrevant Based on Data From PALOMA-3 Study. Im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-gives-nod-expanded-j-160700577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889566641.SGD","LU0345769128.USD","IE0009355771.USD","LU1244550577.SGD","LU1585245621.USD","LU0889565916.HKD","LU2347655156.SGD","LU2417539215.USD","LU1061106388.HKD","IE0034235303.USD","BK4581","IE00BSNM7G36.USD","BK4181","IE00BGHQF631.EUR","LU0466842654.USD","SG9999002224.SGD","BK4533","AZN","IE00BJJMRZ35.SGD","BK4087","BK4213","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1914381329.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","LU1674673691.USD","LU0795875169.SGD","LU2089984988.USD","LU0203347892.USD","BK4585","JNJ","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","CHMP","IE0002270589.USD","LU1059921491.USD","LU0912757837.SGD","BK4534","BMRN","CRT","IE00B7SZLL34.SGD","HRMY","LU0320765646.SGD","PK","LU2505996509.AUD","LU1261432733.SGD","BK4139","LU1162221912.USD"],"gpt_icon":0},{"id":"2508468720","title":"4 Stocks That Sport Impressive Interest Coverage Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2508468720","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508468720?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:08","pubTimestamp":1738678080,"startTime":"0","endTime":"0","summary":"Apart from having an Interest Coverage Ratio that is more than the industry average, adding a favorable Zacks Rank and a VGM Score of A or B to your search criteria should lead to better results.Interest Coverage Ratio greater than X-Industry MedianPrice greater than or equal to 5: The stocks must all be trading at a minimum of $5 or higher.5-Year Historical EPS Growth (%) greater than X-Industry Median: Stocks that have a strong EPS growth history.Projected EPS Growth (%) greater than X-Industry Median: This is the projec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-stocks-sport-impressive-interest-140800918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4209","BK4139","ENSG","EBIT","IE0002270589.USD","IE00B19Z3B42.SGD","BK4585","BMRN","CAKE","LU0006061336.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LDOS","BK4123","BK4185","BK4588","BK4566"],"gpt_icon":0},{"id":"2508489467","title":"Biomarin Pharmaceutical Inc : Morgan Stanley  Cuts Target Price to $105 From $112","url":"https://stock-news.laohu8.com/highlight/detail?id=2508489467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508489467?lang=en_us&edition=fundamental","pubTime":"2025-02-04 14:46","pubTimestamp":1738651560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nAZN3A6NT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","BMRN","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4139"],"gpt_icon":0},{"id":"2508120507","title":"BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2508120507","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508120507?lang=en_us&edition=fundamental","pubTime":"2025-02-04 02:34","pubTimestamp":1738607640,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use  of the European Medicines Agency for two of its drugs.The CHMP recommended approval of Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .The CHMP also recommended approval of Breyanzi  for relapsed or refractory follicular lymphoma.Shares of BMY have risen 29.8% in the past year against the industry’s decline of 8.7%.The positive CHMP opinion was based on late-stage CheckMate -9DW trial, which demonstrated statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in RCC patients.We note that Breyanzi is currently approved in the EU for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , high-grade B-cell lymphoma , primary mediastinal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmy-gets-positive-chmp-opinion-183400618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","IE00BJJMRZ35.SGD","LU0225284248.USD","LU1291159041.SGD","LU0456855351.SGD","CHMP","LU0306806265.USD","LU2125154935.USD","LU2242652126.USD","LU2133065610.SGD","LU1323610961.USD","LU1868836914.USD","ALNY","LU1670710661.SGD","BMY","IE00B2B36J28.USD","LU1989771016.USD","HCC","IE00B7SZLL34.SGD","BK4532","LU1670710588.SGD","LU2360032135.SGD","BK4588","LU1093756168.USD","BK4022","IE00BFTCPJ56.SGD","LU0096364046.USD","LU0321505439.SGD","BK4006","LU0882574055.USD","LU1261432733.SGD","IE0002141913.USD","IE0002270589.USD","LU1585245621.USD","IE0009355771.USD","LU1074936037.SGD","LU1868837300.USD","LU2242646821.SGD","CAR","LU1670711040.USD","LU0225771236.USD","BMRN","IE00B19Z3581.USD","LU1868837136.USD","LU1718418525.SGD","BK4007","EXEL","BK4548","LU0985481810.HKD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2508512562","title":"Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=2508512562","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508512562?lang=en_us&edition=fundamental","pubTime":"2025-02-03 23:53","pubTimestamp":1738597980,"startTime":"0","endTime":"0","summary":"Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec as well as those acquired from Seagen . The trend is expected to have continued in the fourth quarter.In the past year, Pfizer’s stock has declined 0.2% compared with a decrease of 2.5% for the industry.Vyndaqel/Vyndamax sales are likely to have benefited from continued demand growth, primarily in the United States and developed Europe.Among other acquired products, Nurtec sales are likely to have improved sequentially, driven by strong demand in the United States and launches in international markets. However, regarding another newly acquired drug, Oxbryta, in September, Pfizer announced that it is voluntarily withdrawing all lots of the sickle cell disease drug from all global markets where it is approved. Sales of Oxbryta are likely to have be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/non-covid-drugs-drive-pfes-155300754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFE","ALNY","BMRN"],"gpt_icon":1},{"id":"2508142643","title":"BofA Adjusts Price Target on BioMarin Pharmaceutical to $99 From $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2508142643","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508142643?lang=en_us&edition=fundamental","pubTime":"2025-02-03 23:26","pubTimestamp":1738596396,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical (BMRN) has an average rating of overweight and mean price target of $95.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMRN"],"gpt_icon":0},{"id":"2508998150","title":"VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2508998150","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508998150?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:56","pubTimestamp":1738338960,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.Per the company, Journavx has the potential to transform the treatment paradigm of acute pain. Pain is an area with limited treatment options, mostly highly addictive opioid-based medications.Vertex believes Journavx, a non-opioid drug, is an effective and well-tolerated medicine for use in all types of moderate-to-severe acute pain.Shares of VRTX were up more than 8% in after-hours trading on Jan. 30 following the news announcement. The stock was also up in pre-market trading on Jan. 31.Besides acute pain, suzetrigine is also bein","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vrtx-gets-fda-nod-non-155600022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","IE00B19Z9Z06.USD","LU0757428866.USD","BK4567","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU2362541273.HKD","LU2456880835.USD","LU0058720904.USD","VRTX","LU1815336091.USD","LU2462157665.USD","LU0889565916.HKD","IE00B19Z9P08.USD","LU1585245621.USD","BK4196","BK4566","CSTL","LU0061475181.USD","LU0417517546.SGD","BK4588","LU2236285917.USD","LU1093756325.SGD","BK4007","LU1035775433.USD","BK4532","LU1430594728.SGD","IE00B894F039.SGD","LU0289739699.SGD","LU2237438978.USD","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","BK4533","LU0256863811.USD","LU0109394709.USD","IE00B19Z3B42.SGD","VERX","BK4139","IE00B7SZLL34.SGD","LU1559883803.SGD","LU2362541513.USD","IE00BJT1NW94.SGD","BMRN","BK4023","HRMY","LU1069344957.HKD","LU2362540622.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2508998698","title":"Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2508998698","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508998698?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:51","pubTimestamp":1738338660,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo  for the acute treatment of migraine with or without aura in adults.Per the company, Symbravo, a novel, oral medicine, offers a multi-mechanistic approach to treating migraine. It targets multiple pathways underlying a migraine attack.AXSM expects to launch Symbravo in the United States in about four months.Shares of AXSM were up 3.5% on Jan. 30 following the news announcement.The stock has rallied 20.8% in the past year against the industry’s decline of 10.2%.Axsome’s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.The acquisition of Sunosi from Jazz diversified Axsome’s portfolio of drugs. In the first nine months of 2024, Sunosi’s net product sales were $65.6 million, reflecting an increase of alm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-gets-fda-nod-migraine-155100511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AXSM","IE00BN0W2W23.USD","LU0889565916.HKD","IE00BN0W2V16.EUR","BMRN","HRMY","BK4532","BK4139","IE0002270589.USD","BK4585","LU0109394709.USD","IE00B19Z3581.USD","BK4007","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","BK4505","JAZZ","IE00BN0W2T93.GBP","BK4533","LU0320765992.SGD"],"gpt_icon":1},{"id":"2508499339","title":"CMRX Stock Skyrockets in 3 Months: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2508499339","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508499339?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:43","pubTimestamp":1738338180,"startTime":"0","endTime":"0","summary":"Shares of Chimerix CMRX have skyrocketed 323.7% in the past three months following the company’s submission of a new drug application  to the FDA, seeking accelerated approval for its lead candidate, dordaviprone, to treat patients with recurrent H3 K27M-mutant diffuse glioma. CMRX’s dordaviprone is a first-in-class small molecule imipridone with a novel mechanism of action.Chimerix has also requested the FDA to grant the Priority Review status to the dordaviprone NDA filing for the glioma indication. A filing accepted under the regulatory body’s Priority Review pathway reduces the review period to six months from the standard 10 months. This status is given to treatments that the FDA believes, could significantly improve existing options or provide solutions where no approved therapy exists. Subject to a grant from the FDA, a final decision is expected in the third quarter of 2025.Please note that CMRX’s dordaviprone already enjoys the Rare Pediatric Disease Designation for H3 K27M-mu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cmrx-stock-skyrockets-3-months-154300643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4196","BK4585","IE00B19Z3581.USD","BK4139","BK4566","BK4583","IE00B7SZLL34.SGD","IE0002270589.USD","BK4588","CMRX","ALNY","IE00B19Z3B42.SGD","CSTL","BMRN"],"gpt_icon":0},{"id":"2507671365","title":"IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2507671365","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507671365?lang=en_us&edition=fundamental","pubTime":"2025-01-31 00:48","pubTimestamp":1738255680,"startTime":"0","endTime":"0","summary":"Ironwood Pharmaceuticals, Inc. IRWD announced that it has initiated the rolling new drug application  submission for the next-generation GLP-2 analog, apraglutide, for treating short bowel syndrome  patients who are dependent on parenteral support.The NDA filing is expected to be completed in the third quarter of 2025.The company also announced a corporate restructuring and a strategic reorganization. IRWD has decided to reduce its current workforce by almost 50% to achieve long-term growth.Shares of Ironwood were down 11.6% yesterday following the announcement.The stock has plunged 73.8% in the past year compared with the industry’s decline of 5.8%.The phase III STARS study evaluated apraglutide for reducing parenteral support dependency in adult patients with short bowel syndrome with intestinal failure . The open-label extension study, STARS Extend, also evaluated apraglutide for the given indication.Data from the open-label extension study showed that treatment with apraglutide led","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/irwd-begins-apraglutide-nda-submission-164800782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","LU1551013425.SGD","BK4581","LU0708994859.HKD","LU1023059063.AUD","IE00BSNM7G36.USD","IE00BDGV0183.EUR","SG9999011175.SGD","ABBV","LU2023251221.USD","LU1496350171.SGD","BMRN","IE0004445239.USD","BK4550","LU2347655156.SGD","BK4139","LU0820561909.HKD","IE00B19Z3B42.SGD","LU0128525929.USD","LU0912757837.SGD","LU0122379950.USD","LU0689472784.USD","LU2112291526.USD","LU0203345920.USD","IE00BJJMRZ35.SGD","SG9999015986.USD","LU0234570918.USD","LU1244550221.USD","LU0965508806.USD","LU0965509283.SGD","IE00B42XCP33.USD","LU1093756168.USD","IE00B3PB1722.GBP","LU1037948541.HKD","LU1989772840.SGD","RIGL","SG9999015952.SGD","LU1934455194.USD","LU1934455863.HKD","IRWD","SG9999003800.SGD","LU0158827948.USD","LU0456855351.SGD","LU0256863811.USD","IE0002270589.USD","IE00B4R5TH58.HKD","LU1244550494.USD","LU0211328371.USD","LU1839511570.USD","LU0985320562.USD"],"gpt_icon":0},{"id":"2507733036","title":"Why This 1 Value Stock Could Be a Great Addition to Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2507733036","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507733036?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:40","pubTimestamp":1738248011,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.A company's earnings performance is important for value investors as well. For fiscal 2024, one analyst revised their earnings estimate higher in the last 60 days for BMRN, while the Zacks Conse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-1-value-stock-could-144011852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BMRN","BK4566","IE00B19Z3581.USD","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2507487654","title":"FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2507487654","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507487654?lang=en_us&edition=fundamental","pubTime":"2025-01-30 00:34","pubTimestamp":1738168440,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug  application to begin clinical studies on its investigational CRISPR-based allogenic CAR-T therapy, ALLO-329, for the treatment of various autoimmune diseases.The phase I RESOLUTION basket study will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.The study, which aims to offer a key understanding of ALLO-329's potential to transform the treatment paradigm across a range of autoimmune diseases, is expected to begin in mid-2025. The company expects to have proof-of-concept from the basket study by the end of 2025.A next-generation allogeneic CAR T-cell therapy, ALLO-329, works by targeting both CD19+ B-cells and CD70+ activated T-cells. Additionally, the candidate incorporates ALLO’s proprietary Dagger technology, which is designed to reduce or eliminat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-clears-allogenes-ind-car-163400440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","CSTL","BMRN","IE00B19Z3581.USD","IE0002270589.USD","ALLO","BK4007","BK4196","BK4139","CAR","BK4566","HRMY","IE00B19Z3B42.SGD","BK4505"],"gpt_icon":0},{"id":"2507611549","title":"FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2507611549","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507611549?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:11","pubTimestamp":1738080660,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application  seeking approval for expanded use of Enhertu  for HER2-low metastatic breast cancer in the United States. The approval of the added indication has triggered a $175 million milestone payment from AstraZeneca to Daiichi Sankyo.The companies’ sBLA was seeking approval for Enhertu to treat unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting.The nod in the United States expands the approved indication of Enhertu in HER2-low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2-ultralow. The drug has earlier received the FDA’s Breakthrough Therapy designation in the United States for this new indication.In three months, shares of AstraZeneca have lost 6.8% compared with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-label-azns-enhertu-161100900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2417539215.USD","BK4548","DSKYF","LU2236285917.USD","BK4211","PFS","DSNKY","IE0002270589.USD","IE00B19Z3581.USD","LU0109394709.USD","IE00B19Z3B42.SGD","BK4588","BK4007","BK4080","LU0320765992.SGD","CSTL","ADC","BK4585","IE00B7SZLL34.SGD","LU2456880835.USD","LU2462157665.USD","BMRN","BK4566","BK4231","LU0889565916.HKD","BK4139","ALNY","AZN","LU1829250122.USD","BK4195","BK4196","BK4568"],"gpt_icon":0},{"id":"2506584565","title":"Is BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506584565","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506584565?lang=en_us&edition=fundamental","pubTime":"2025-01-28 04:04","pubTimestamp":1738008295,"startTime":"0","endTime":"0","summary":"We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. stands against other best depressed stocks to invest in now.The US stocks ended 2024 with a healthy Q4, as the equity markets were primarily aided by solid economic growth, healthy earnings momentum, and the expectations of the rate cuts. Morningstar highlighted that theresults of the US election supported the broader momentum in November. However, in December, the markets were shocked when the US Fed reduced projections for more cuts. Also, the quarter was difficult for bonds as yields continued to jump.With Trump 2.0 and some positive expectations regarding risky assets, what lies ahead for investors in 2025?What’s in Store for S&P 500 Index in 2025?READ ALSO:7 Best Stocks to Buy For Long-Termand8 Cheap Jim Cramer Stocks to Invest In.To list the 12 Best Depressed Stocks to Invest in Now, we used a screener to filter out the stoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomarin-pharmaceutical-bmrn-best-depressed-200455574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","USAW.SI","NVIW.SI","IVV",".SPX","SSO","NQmain","BK4504","BMRN","BK4559","OEX","BK4139","ESmain","QID","SPY","BK4581","MNQmain","UPRO","IE0002270589.USD","BK4585","IE00B19Z3581.USD","BK4588","PSQ","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD",".IXIC","USJW.SI","SQQQ","TSYW.SI","OEF","SDS","SH","VOO","BK4550","SPXU","BK4534","TQQQ"],"gpt_icon":1},{"id":"2506832715","title":"BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506832715","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506832715?lang=en_us&edition=fundamental","pubTime":"2025-01-28 00:40","pubTimestamp":1737996014,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical  and CSL Limited Sponsored ADR . But which of these two stocks presents investors with the better value opportunity right now?We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.Currently, BioMarin Pharmaceutical has a Zacks Rank of #1 , while CSL Limited Sponsored ADR has a Zacks Rank of #3 . The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BMRN has an improving earnings outlook. However, value investors will care about much more than just this.BioMarin Pharmaceutical Inc.  : Free Stock Analysis Report. CSL Limited Sponsored ADR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmrn-vs-cslly-stock-value-164014669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ISBC","BK4566","IE00B19Z3581.USD","BK7508","BK4139","IE00B19Z3B42.SGD","IE0002270589.USD","BK7067","BK7501","IE00B7SZLL34.SGD","BMRN","BK4211","CSL.AU","BK7511","CSLLY"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMRN\",params:#limit:5,,,undefined,":[{"date":"2025-05-01","symbol":"BMRN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.75,"defaultRemindTime":1746129600000,"name":null,"time":"Post Market","dateTimestamp":1746072000000,"actualEps":null},{"market":"US","date":"2025-02-19","symbol":"BMRN","fiscalQuarterEnding":"2024/12","expectedEps":0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739941200000,"reportTimeType":"post","actualEps":0.72},{"market":"US","date":"2024-10-29","symbol":"BMRN","fiscalQuarterEnding":"2024/09","expectedEps":0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730174400000,"reportTimeType":"post","actualEps":0.74},{"market":"US","date":"2024-08-05","symbol":"BMRN","fiscalQuarterEnding":"2024/06","expectedEps":0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.77},{"market":"US","date":"2024-04-24","symbol":"BMRN","fiscalQuarterEnding":"2024/03","expectedEps":0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"post","actualEps":0.49}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMRN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMRN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3448,"buy":0.4483,"hold":0.2069,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4483,"analysts":29,"updateTime":1740456000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BMRN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BMRN","date":"2025-04-17","current":26.423199,"percent":0.244698,"low":-742.431892,"twenty":18.323094,"median":112.852143,"eighty":244.60049,"high":1069.125802,"avg":167.492096,"sd":259.828409,"marketCap":11278980279},"quantilePoints":[{"date":"2020-04-24","current":-737.580882,"twenty":-145.315182,"median":-112.264026,"eighty":-74.453642,"marketCap":17589828874},{"date":"2020-05-01","current":139.717537,"twenty":-146.720429,"median":-112.32011,"eighty":-74.102444,"marketCap":15928637554},{"date":"2020-05-08","current":151.00669,"twenty":-146.720429,"median":-112.32011,"eighty":-70.459717,"marketCap":17215668691},{"date":"2020-05-15","current":148.690831,"twenty":-146.720429,"median":-112.264026,"eighty":-67.95747,"marketCap":16951646881},{"date":"2020-05-22","current":154.670823,"twenty":-146.720429,"median":-112.009509,"eighty":-65.875106,"marketCap":17633401828},{"date":"2020-05-29","current":169.010114,"twenty":-146.720429,"median":-111.583861,"eighty":-65.266721,"marketCap":19268167006},{"date":"2020-06-05","current":167.82046,"twenty":-146.720429,"median":-111.430067,"eighty":-53.616205,"marketCap":19132539364},{"date":"2020-06-12","current":167.693564,"twenty":-146.720429,"median":-111.166002,"eighty":-52.32921,"marketCap":19118072416},{"date":"2020-06-19","current":196.879731,"twenty":-146.720429,"median":-110.643992,"eighty":-51.800638,"marketCap":22445470566},{"date":"2020-06-26","current":196.72111,"twenty":-146.720429,"median":-110.454206,"eighty":-51.112661,"marketCap":22427386881},{"date":"2020-07-02","current":201.099035,"twenty":-146.720429,"median":-110.047751,"eighty":-50.787838,"marketCap":22926496603},{"date":"2020-07-10","current":199.956968,"twenty":-146.720429,"median":-109.640088,"eighty":-50.663322,"marketCap":22796294067},{"date":"2020-07-17","current":203.367308,"twenty":-146.720429,"median":-109.199968,"eighty":-50.401769,"marketCap":23185093307},{"date":"2020-07-24","current":195.023871,"twenty":-146.720429,"median":-109.08296,"eighty":-50.291122,"marketCap":22233891445},{"date":"2020-07-31","current":190.043188,"twenty":-146.720429,"median":-108.761911,"eighty":-50.018415,"marketCap":21666063717},{"date":"2020-08-07","current":176.02739,"twenty":-146.720429,"median":-108.266562,"eighty":-49.711244,"marketCap":21520756675},{"date":"2020-08-14","current":175.270889,"twenty":-146.720429,"median":-107.874867,"eighty":-49.409876,"marketCap":21428268381},{"date":"2020-08-21","current":111.294641,"twenty":-146.720429,"median":-107.54787,"eighty":-49.282149,"marketCap":13606660262},{"date":"2020-08-28","current":113.297144,"twenty":-146.720429,"median":-107.159772,"eighty":-49.094704,"marketCap":13851482218},{"date":"2020-09-04","current":112.733477,"twenty":-146.720429,"median":-106.448863,"eighty":-48.818303,"marketCap":13782569372},{"date":"2020-09-11","current":106.874302,"twenty":-146.720429,"median":-105.912505,"eighty":-48.569168,"marketCap":13066238463},{"date":"2020-09-18","current":117.74715,"twenty":-146.720429,"median":-105.43525,"eighty":-48.312221,"marketCap":14395531009},{"date":"2020-09-25","current":114.795312,"twenty":-146.720429,"median":-104.968329,"eighty":-48.052471,"marketCap":14034645311},{"date":"2020-10-02","current":111.220475,"twenty":-146.720429,"median":-104.968329,"eighty":-47.767481,"marketCap":13597592783},{"date":"2020-10-09","current":116.960982,"twenty":-146.720429,"median":-104.968329,"eighty":-47.469759,"marketCap":14299415723},{"date":"2020-10-16","current":117.554316,"twenty":-146.720429,"median":-104.968329,"eighty":-47.31175,"marketCap":14371955562},{"date":"2020-10-23","current":115.002979,"twenty":-146.720429,"median":-104.968329,"eighty":-47.07446,"marketCap":14060034255},{"date":"2020-10-30","current":110.40464,"twenty":-146.720429,"median":-104.968329,"eighty":-46.453512,"marketCap":13497850504},{"date":"2020-11-06","current":16.333756,"twenty":-145.315182,"median":-104.024299,"eighty":-46.24616,"marketCap":13916768073},{"date":"2020-11-13","current":16.516158,"twenty":-144.868574,"median":-103.498065,"eighty":-45.910184,"marketCap":14072179785},{"date":"2020-11-20","current":16.181659,"twenty":-144.868574,"median":-102.889101,"eighty":-45.353548,"marketCap":13787178208},{"date":"2020-11-27","current":17.129762,"twenty":-144.868574,"median":-102.47937,"eighty":-34.458654,"marketCap":14594985226},{"date":"2020-12-04","current":16.961447,"twenty":-144.868574,"median":-101.666821,"eighty":-33.817892,"marketCap":14451576789},{"date":"2020-12-11","current":16.93588,"twenty":-144.868574,"median":-101.332926,"eighty":-32.987662,"marketCap":14429793229},{"date":"2020-12-18","current":18.930091,"twenty":-144.868574,"median":-100.855221,"eighty":-31.786506,"marketCap":16128910912},{"date":"2020-12-24","current":18.88961,"twenty":-144.868574,"median":-100.530187,"eighty":-31.699842,"marketCap":16094420276},{"date":"2020-12-31","current":18.682945,"twenty":-144.868574,"median":-100.130791,"eighty":-31.545183,"marketCap":15918336499},{"date":"2021-01-08","current":19.145278,"twenty":-144.868574,"median":-99.499409,"eighty":-31.239921,"marketCap":16312255876},{"date":"2021-01-15","current":17.677318,"twenty":-144.868574,"median":-99.011614,"eighty":-31.142754,"marketCap":15061516470},{"date":"2021-01-22","current":18.746862,"twenty":-144.868574,"median":-98.307572,"eighty":-30.998361,"marketCap":15972795399},{"date":"2021-01-29","current":17.636837,"twenty":-144.868574,"median":-97.576033,"eighty":-30.940261,"marketCap":15027025834},{"date":"2021-02-05","current":18.156695,"twenty":-144.868574,"median":-97.576033,"eighty":-30.85726,"marketCap":15469958221},{"date":"2021-02-12","current":18.544458,"twenty":-144.868574,"median":-97.576033,"eighty":-30.741472,"marketCap":15800342215},{"date":"2021-02-19","current":17.419519,"twenty":-144.868574,"median":-97.521381,"eighty":-30.612592,"marketCap":14841865573},{"date":"2021-02-26","current":16.477433,"twenty":-144.868574,"median":-95.195111,"eighty":-30.351921,"marketCap":14072205552},{"date":"2021-03-05","current":16.549346,"twenty":-144.931156,"median":-92.988484,"eighty":-30.193594,"marketCap":14133621026},{"date":"2021-03-12","current":16.344954,"twenty":-144.931156,"median":-92.037344,"eighty":-30.118727,"marketCap":13959064533},{"date":"2021-03-19","current":16.645154,"twenty":-144.931156,"median":-90.941505,"eighty":-29.706846,"marketCap":14215444382},{"date":"2021-03-26","current":16.070302,"twenty":-144.868574,"median":-89.639785,"eighty":-29.214173,"marketCap":13724504246},{"date":"2021-04-01","current":16.570636,"twenty":-144.868574,"median":-88.5032,"eighty":-28.439397,"marketCap":14151803994},{"date":"2021-04-09","current":16.408826,"twenty":-144.931156,"median":-87.602744,"eighty":-27.75353,"marketCap":14013613437},{"date":"2021-04-16","current":16.904902,"twenty":-144.931156,"median":-86.817737,"eighty":-27.498326,"marketCap":14437276592},{"date":"2021-04-23","current":16.838842,"twenty":-144.931156,"median":-86.272203,"eighty":-27.151224,"marketCap":14380859669},{"date":"2021-04-30","current":17.900998,"twenty":-144.931156,"median":-85.694758,"eighty":15.913176,"marketCap":14232904679},{"date":"2021-05-07","current":17.874568,"twenty":-144.931156,"median":-85.610935,"eighty":16.023777,"marketCap":14211889902},{"date":"2021-05-14","current":17.681503,"twenty":-144.931156,"median":-85.219763,"eighty":16.210666,"marketCap":14058386140},{"date":"2021-05-21","current":17.950414,"twenty":-144.931156,"median":-84.959558,"eighty":16.297129,"marketCap":14272194951},{"date":"2021-05-28","current":17.766543,"twenty":-144.931156,"median":-84.679572,"eighty":16.395247,"marketCap":14126000892},{"date":"2021-06-04","current":17.902148,"twenty":-144.931156,"median":-84.297713,"eighty":16.432736,"marketCap":14233819010},{"date":"2021-06-11","current":18.862875,"twenty":-144.931156,"median":-84.279085,"eighty":16.501579,"marketCap":14997682966},{"date":"2021-06-18","current":18.823802,"twenty":-144.931156,"median":-84.279085,"eighty":16.577449,"marketCap":14966616728},{"date":"2021-06-25","current":19.488036,"twenty":-144.931156,"median":-84.279085,"eighty":16.648523,"marketCap":15494742764},{"date":"2021-07-02","current":19.644327,"twenty":-144.931156,"median":-84.279085,"eighty":16.690717,"marketCap":15619007714},{"date":"2021-07-09","current":19.219125,"twenty":-144.931156,"median":-84.185949,"eighty":16.765656,"marketCap":15280933954},{"date":"2021-07-16","current":18.120495,"twenty":-144.931156,"median":-83.841344,"eighty":16.854046,"marketCap":14407424455},{"date":"2021-07-23","current":17.706785,"twenty":-144.931156,"median":-83.683013,"eighty":16.951792,"marketCap":14078487823},{"date":"2021-07-30","current":16.8013,"twenty":-144.931156,"median":-83.422231,"eighty":17.027349,"marketCap":14066283248},{"date":"2021-08-06","current":17.110693,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":14325311683},{"date":"2021-08-13","current":16.431784,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":13756919692},{"date":"2021-08-20","current":16.455874,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":13777088440},{"date":"2021-08-27","current":18.288928,"twenty":-144.931156,"median":-82.965863,"eighty":17.151762,"marketCap":15311746815},{"date":"2021-09-03","current":18.604292,"twenty":-144.931156,"median":-82.965863,"eighty":17.265235,"marketCap":15575774062},{"date":"2021-09-10","current":17.077843,"twenty":-144.931156,"median":-82.965863,"eighty":17.275493,"marketCap":14297808844},{"date":"2021-09-17","current":17.029662,"twenty":-144.931156,"median":-82.965863,"eighty":17.275493,"marketCap":14257471348},{"date":"2021-09-24","current":17.213624,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14411487243},{"date":"2021-10-01","current":16.89826,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14147459995},{"date":"2021-10-08","current":17.044992,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14270306006},{"date":"2021-10-15","current":16.620127,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":13914602631},{"date":"2021-10-22","current":16.14927,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":13520395283},{"date":"2021-10-29","current":913.742979,"twenty":-144.931156,"median":-82.965863,"eighty":17.356508,"marketCap":14544047003},{"date":"2021-11-05","current":967.9689,"twenty":-144.931156,"median":-82.965863,"eighty":17.405709,"marketCap":15407160981},{"date":"2021-11-12","current":942.70851,"twenty":-144.931156,"median":-82.965863,"eighty":17.560148,"marketCap":15005091360},{"date":"2021-11-19","current":1055.053805,"twenty":-144.931156,"median":-82.965863,"eighty":17.678992,"marketCap":16793291407},{"date":"2021-11-26","current":1010.184893,"twenty":-144.931156,"median":-82.965863,"eighty":17.719077,"marketCap":16079112949},{"date":"2021-12-03","current":956.780508,"twenty":-144.931156,"median":-82.965863,"eighty":17.763785,"marketCap":15229075350},{"date":"2021-12-10","current":979.157292,"twenty":-144.931156,"median":-82.965863,"eighty":17.780334,"marketCap":15585246612},{"date":"2021-12-17","current":997.497027,"twenty":-144.931156,"median":-82.965863,"eighty":17.854801,"marketCap":15877160172},{"date":"2021-12-23","current":1051.478133,"twenty":-144.931156,"median":-82.965863,"eighty":17.921454,"marketCap":16736377443},{"date":"2021-12-31","current":1019.0664,"twenty":-144.931156,"median":-82.965863,"eighty":18.068316,"marketCap":16220479893},{"date":"2022-01-07","current":971.77526,"twenty":-144.868574,"median":-82.756306,"eighty":18.102568,"marketCap":15467746814},{"date":"2022-01-14","current":1040.635774,"twenty":-144.868574,"median":-82.756306,"eighty":18.18902,"marketCap":16563799615},{"date":"2022-01-21","current":976.38903,"twenty":-144.868574,"median":-82.756306,"eighty":18.272526,"marketCap":15541184188},{"date":"2022-01-28","current":993.806011,"twenty":-144.868574,"median":-82.756306,"eighty":18.302,"marketCap":15818410273},{"date":"2022-02-04","current":1022.296039,"twenty":-144.868574,"median":-82.756306,"eighty":18.385092,"marketCap":16271886055},{"date":"2022-02-11","current":1048.594527,"twenty":-144.868574,"median":-82.756306,"eighty":18.50696,"marketCap":16690479084},{"date":"2022-02-18","current":978.811259,"twenty":-144.868574,"median":-82.756306,"eighty":18.612353,"marketCap":15579738809},{"date":"2022-02-25","current":-223.863547,"twenty":-146.720429,"median":-83.128851,"eighty":18.645295,"marketCap":14345176092},{"date":"2022-03-04","current":-219.184373,"twenty":-148.717362,"median":-83.543308,"eighty":18.645295,"marketCap":14045334603},{"date":"2022-03-11","current":-218.207922,"twenty":-159.853208,"median":-83.818061,"eighty":18.645295,"marketCap":13982763668},{"date":"2022-03-18","current":-234.549105,"twenty":-161.293219,"median":-83.967078,"eighty":18.645295,"marketCap":15029906670},{"date":"2022-03-25","current":-226.938537,"twenty":-162.185225,"median":-84.288399,"eighty":18.645295,"marketCap":14542221441},{"date":"2022-04-01","current":-227.656515,"twenty":-163.361234,"median":-84.633004,"eighty":18.645295,"marketCap":14588229481},{"date":"2022-04-08","current":-246.955768,"twenty":-164.641244,"median":-84.986921,"eighty":18.645295,"marketCap":15824925610},{"date":"2022-04-14","current":-238.225154,"twenty":-165.041247,"median":-85.857746,"eighty":18.645295,"marketCap":15265467837},{"date":"2022-04-22","current":-232.276832,"twenty":-165.973254,"median":-88.12096,"eighty":18.645295,"marketCap":14884299384},{"date":"2022-04-29","current":382.277246,"twenty":-166.445258,"median":-90.308931,"eighty":18.664196,"marketCap":15041462794},{"date":"2022-05-06","current":372.455987,"twenty":-166.445258,"median":-89.349626,"eighty":18.760072,"marketCap":14655025704},{"date":"2022-05-13","current":365.458317,"twenty":-166.445258,"median":-89.349626,"eighty":18.859197,"marketCap":14379688400},{"date":"2022-05-20","current":374.814577,"twenty":-166.445258,"median":-89.349626,"eighty":18.955948,"marketCap":14747829142},{"date":"2022-05-27","current":380.691624,"twenty":-166.445258,"median":-89.349626,"eighty":19.066512,"marketCap":14979073327},{"date":"2022-06-03","current":364.329924,"twenty":-166.445258,"median":-89.349626,"eighty":19.178673,"marketCap":14335289516},{"date":"2022-06-10","current":352.998976,"twenty":-166.445258,"median":-89.349626,"eighty":19.261875,"marketCap":13889450727},{"date":"2022-06-17","current":357.700614,"twenty":-166.445258,"median":-89.349626,"eighty":19.519294,"marketCap":14074446075},{"date":"2022-06-24","current":408.337255,"twenty":-166.509258,"median":-86.272203,"eighty":107.93637,"marketCap":16066845973},{"date":"2022-07-01","current":399.545192,"twenty":-166.509258,"median":-84.809963,"eighty":110.39574,"marketCap":15720904673},{"date":"2022-07-08","current":418.539809,"twenty":-166.509258,"median":-84.754081,"eighty":111.051374,"marketCap":16468285878},{"date":"2022-07-15","current":409.418632,"twenty":-166.509258,"median":-83.152135,"eighty":111.935442,"marketCap":16109394903},{"date":"2022-07-22","current":400.720602,"twenty":-166.509258,"median":-83.077626,"eighty":112.591077,"marketCap":15767153510},{"date":"2022-07-29","current":404.575945,"twenty":-166.509258,"median":-81.708522,"eighty":113.113211,"marketCap":15918849695},{"date":"2022-08-05","current":327.838991,"twenty":-166.509258,"median":-34.536978,"eighty":114.110012,"marketCap":17726254245},{"date":"2022-08-12","current":325.272938,"twenty":-166.509258,"median":-34.536978,"eighty":114.976279,"marketCap":17587507734},{"date":"2022-08-19","current":318.464838,"twenty":-166.509258,"median":-34.536978,"eighty":115.685314,"marketCap":17219393812},{"date":"2022-08-26","current":312.187472,"twenty":-166.509258,"median":-34.536978,"eighty":116.907582,"marketCap":16879976635},{"date":"2022-09-02","current":307.488024,"twenty":-166.509258,"median":-34.536978,"eighty":117.883617,"marketCap":16625877437},{"date":"2022-09-09","current":318.773561,"twenty":-166.509258,"median":-34.536978,"eighty":141.162306,"marketCap":17236086460},{"date":"2022-09-16","current":302.58276,"twenty":-166.509258,"median":-34.536978,"eighty":148.167383,"marketCap":16360649808},{"date":"2022-09-23","current":291.022801,"twenty":-166.509258,"median":-34.536978,"eighty":150.289725,"marketCap":15735602876},{"date":"2022-09-30","current":290.782684,"twenty":-166.509258,"median":-34.536978,"eighty":152.726136,"marketCap":15722619705},{"date":"2022-10-07","current":302.376944,"twenty":-166.509258,"median":-34.536978,"eighty":167.017841,"marketCap":16349521376},{"date":"2022-10-14","current":299.289715,"twenty":-166.509258,"median":-34.536978,"eighty":168.933976,"marketCap":16182594895},{"date":"2022-10-21","current":308.757218,"twenty":-166.509258,"median":-34.536978,"eighty":170.628042,"marketCap":16694502768},{"date":"2022-10-28","current":192.178834,"twenty":-166.509258,"median":-34.536978,"eighty":175.146289,"marketCap":16126110354},{"date":"2022-11-04","current":182.699459,"twenty":-166.509258,"median":-34.536978,"eighty":176.471621,"marketCap":15330676998},{"date":"2022-11-11","current":181.968573,"twenty":-166.509258,"median":-34.536978,"eighty":178.346579,"marketCap":15269346856},{"date":"2022-11-18","current":195.589638,"twenty":-166.509258,"median":-34.536978,"eighty":182.260927,"marketCap":16412317683},{"date":"2022-11-25","current":214.659129,"twenty":-166.509258,"median":-34.536978,"eighty":187.341695,"marketCap":18012476841},{"date":"2022-12-02","current":233.795065,"twenty":-166.509258,"median":-34.536978,"eighty":190.997361,"marketCap":19618211467},{"date":"2022-12-09","current":226.641237,"twenty":-166.509258,"median":-34.536978,"eighty":192.536436,"marketCap":19017919471},{"date":"2022-12-16","current":240.594523,"twenty":-166.509258,"median":-34.14536,"eighty":193.90401,"marketCap":20188767636},{"date":"2022-12-23","current":231.093,"twenty":-166.509258,"median":-33.835795,"eighty":195.798534,"marketCap":19391475791},{"date":"2022-12-30","current":229.210413,"twenty":-166.509258,"median":15.910621,"eighty":196.943179,"marketCap":19233504213},{"date":"2023-01-06","current":240.771708,"twenty":-166.509258,"median":15.99843,"eighty":199.747589,"marketCap":20203635549},{"date":"2023-01-13","current":249.653085,"twenty":-166.509258,"median":16.07919,"eighty":201.466427,"marketCap":20948889698},{"date":"2023-01-20","current":245.289915,"twenty":-166.509258,"median":16.188691,"eighty":202.812136,"marketCap":20582767336},{"date":"2023-01-27","current":259.730459,"twenty":-166.509258,"median":16.239185,"eighty":206.755441,"marketCap":21794502262},{"date":"2023-02-03","current":248.501386,"twenty":-166.509258,"median":16.333756,"eighty":220.240444,"marketCap":20852248263},{"date":"2023-02-10","current":242.432813,"twenty":-166.509258,"median":16.413891,"eighty":226.49506,"marketCap":20343022235},{"date":"2023-02-17","current":239.885785,"twenty":-166.509258,"median":16.442734,"eighty":229.440754,"marketCap":20129295983},{"date":"2023-02-24","current":226.065387,"twenty":-166.509258,"median":16.476957,"eighty":230.229225,"marketCap":18969598754},{"date":"2023-03-03","current":133.346847,"twenty":-166.509258,"median":16.516158,"eighty":230.229225,"marketCap":18876712940},{"date":"2023-03-10","current":119.234744,"twenty":-166.509258,"median":16.567292,"eighty":230.229225,"marketCap":16878989664},{"date":"2023-03-17","current":120.789579,"twenty":-166.509258,"median":16.617476,"eighty":230.229225,"marketCap":17099093629},{"date":"2023-03-24","current":119.564159,"twenty":-166.509258,"median":16.650384,"eighty":230.229225,"marketCap":16925621860},{"date":"2023-03-31","current":128.128926,"twenty":-166.445258,"median":16.685656,"eighty":229.9413,"marketCap":18138058956},{"date":"2023-04-06","current":127.246097,"twenty":-166.445258,"median":16.720301,"eighty":229.9413,"marketCap":18013084670},{"date":"2023-04-14","current":129.578349,"twenty":-166.509258,"median":16.77077,"eighty":230.229225,"marketCap":18343240618},{"date":"2023-04-21","current":127.575511,"twenty":-166.509258,"median":16.817229,"eighty":230.229225,"marketCap":18059716866},{"date":"2023-04-28","current":242.180022,"twenty":-166.509258,"median":16.855933,"eighty":231.407502,"marketCap":17343722249},{"date":"2023-05-05","current":250.17182,"twenty":-166.509258,"median":16.91578,"eighty":235.380867,"marketCap":17916054913},{"date":"2023-05-12","current":250.014562,"twenty":-166.573259,"median":16.941683,"eighty":237.019824,"marketCap":17904792857},{"date":"2023-05-19","current":241.732289,"twenty":-166.637259,"median":16.967171,"eighty":239.8282,"marketCap":17311657880},{"date":"2023-05-26","current":232.558885,"twenty":-166.637259,"median":17.014711,"eighty":240.585664,"marketCap":16654704583},{"date":"2023-05-30","current":231.916747,"twenty":-166.637259,"median":17.029662,"eighty":240.585664,"marketCap":16608717852},{"date":"2023-06-09","current":241.810918,"twenty":-166.73726,"median":17.061278,"eighty":241.008901,"marketCap":17317288908},{"date":"2023-06-16","current":251.194,"twenty":-166.74926,"median":17.112883,"eighty":241.385297,"marketCap":17989258281},{"date":"2023-06-23","current":250.591176,"twenty":-166.76126,"median":17.196104,"eighty":241.856963,"marketCap":17946087064},{"date":"2023-06-30","current":233.08308,"twenty":-166.76126,"median":17.241,"eighty":242.23058,"marketCap":16692244772},{"date":"2023-07-07","current":224.355242,"twenty":-166.76126,"median":17.308262,"eighty":242.23058,"marketCap":16067200635},{"date":"2023-07-14","current":224.643549,"twenty":-166.76126,"median":17.371372,"eighty":242.23058,"marketCap":16087847738},{"date":"2023-07-21","current":229.439928,"twenty":-166.76126,"median":17.48024,"eighty":242.23058,"marketCap":16431340462},{"date":"2023-07-28","current":226.871375,"twenty":-166.76126,"median":17.641098,"eighty":242.23058,"marketCap":16247393539},{"date":"2023-08-04","current":165.119407,"twenty":-166.76126,"median":17.695247,"eighty":242.23058,"marketCap":16510454583},{"date":"2023-08-11","current":171.085084,"twenty":-166.76126,"median":17.746561,"eighty":242.23058,"marketCap":17106968613},{"date":"2023-08-18","current":168.243389,"twenty":-166.76126,"median":17.778035,"eighty":242.23058,"marketCap":16822824706},{"date":"2023-08-25","current":175.281759,"twenty":-166.76126,"median":17.843539,"eighty":242.23058,"marketCap":17526598357},{"date":"2023-09-01","current":171.969585,"twenty":-166.76126,"median":17.901573,"eighty":242.23058,"marketCap":17195410756},{"date":"2023-09-08","current":170.162944,"twenty":-166.76126,"median":18.020515,"eighty":242.23058,"marketCap":17014762974},{"date":"2023-09-15","current":165.006492,"twenty":-166.76126,"median":18.09038,"eighty":242.23058,"marketCap":16499164096},{"date":"2023-09-22","current":162.352988,"twenty":-166.76126,"median":18.138595,"eighty":242.23058,"marketCap":16233837666},{"date":"2023-09-29","current":167.961101,"twenty":-166.76126,"median":18.255988,"eighty":242.23058,"marketCap":16794598490},{"date":"2023-10-06","current":164.272544,"twenty":-166.76126,"median":18.295251,"eighty":242.23058,"marketCap":16425775935},{"date":"2023-10-13","current":162.861106,"twenty":-166.76126,"median":18.372948,"eighty":242.23058,"marketCap":16284644855},{"date":"2023-10-20","current":155.427533,"twenty":-166.76126,"median":18.480739,"eighty":242.23058,"marketCap":15541354502},{"date":"2023-10-27","current":154.260745,"twenty":-166.76126,"median":18.544458,"eighty":242.382255,"marketCap":15424686142},{"date":"2023-11-03","current":102.060294,"twenty":-166.76126,"median":18.649124,"eighty":242.382255,"marketCap":15005006530},{"date":"2023-11-10","current":107.264835,"twenty":-166.76126,"median":18.746862,"eighty":242.382255,"marketCap":15770183276},{"date":"2023-11-17","current":111.736338,"twenty":-166.76126,"median":18.837592,"eighty":242.382255,"marketCap":16427588192},{"date":"2023-11-24","current":112.991947,"twenty":-166.76126,"median":18.922633,"eighty":242.382255,"marketCap":16612189000},{"date":"2023-12-01","current":116.69471,"twenty":-166.76126,"median":18.980092,"eighty":242.382255,"marketCap":17156573014},{"date":"2023-12-08","current":121.64027,"twenty":-166.76126,"median":19.115548,"eighty":242.331697,"marketCap":17883674154},{"date":"2023-12-15","current":125.073975,"twenty":-166.76126,"median":19.224871,"eighty":242.331697,"marketCap":18388500853},{"date":"2023-12-22","current":121.922141,"twenty":-166.76126,"median":19.421383,"eighty":242.331697,"marketCap":17925115152},{"date":"2023-12-29","current":124.446171,"twenty":-166.76126,"median":97.655587,"eighty":242.382255,"marketCap":18296200449},{"date":"2024-01-05","current":125.21491,"twenty":-166.76126,"median":106.724665,"eighty":242.432813,"marketCap":18409221351},{"date":"2024-01-12","current":122.998377,"twenty":-166.76126,"median":107.662485,"eighty":242.432813,"marketCap":18083344416},{"date":"2024-01-19","current":118.552498,"twenty":-166.79726,"median":109.532617,"eighty":242.575773,"marketCap":17429706862},{"date":"2024-01-26","current":116.91252,"twenty":-166.76126,"median":110.397223,"eighty":242.432813,"marketCap":17188595603},{"date":"2024-02-02","current":113.696625,"twenty":-166.76126,"median":111.153724,"eighty":242.432813,"marketCap":16715791494},{"date":"2024-02-09","current":112.940697,"twenty":-166.76126,"median":111.821225,"eighty":242.432813,"marketCap":16604654273},{"date":"2024-02-16","current":113.132882,"twenty":-166.76126,"median":112.099749,"eighty":242.432813,"marketCap":16632909499},{"date":"2024-02-23","current":101.214924,"twenty":-166.70126,"median":112.294622,"eighty":242.432813,"marketCap":16968175915},{"date":"2024-03-01","current":97.103598,"twenty":-165.901253,"median":112.199476,"eighty":242.382255,"marketCap":16278932666},{"date":"2024-03-08","current":96.664673,"twenty":-164.837246,"median":112.199476,"eighty":242.382255,"marketCap":16205349173},{"date":"2024-03-15","current":94.976502,"twenty":-164.11324,"median":112.199476,"eighty":242.382255,"marketCap":15922335740},{"date":"2024-03-22","current":94.661377,"twenty":-162.221226,"median":112.199476,"eighty":242.382255,"marketCap":15869506566},{"date":"2024-03-28","current":99.72589,"twenty":-162.081225,"median":112.199476,"eighty":242.382255,"marketCap":16718546865},{"date":"2024-04-05","current":97.790121,"twenty":-160.981216,"median":112.294622,"eighty":242.432813,"marketCap":16394024795},{"date":"2024-04-12","current":103.533211,"twenty":-131.648601,"median":112.294622,"eighty":242.432813,"marketCap":17356825158},{"date":"2024-04-19","current":101.959724,"twenty":-125.404689,"median":112.294622,"eighty":242.432813,"marketCap":17093037852},{"date":"2024-04-26","current":75.899547,"twenty":-124.450186,"median":112.199476,"eighty":242.382255,"marketCap":15593941332},{"date":"2024-05-03","current":77.447263,"twenty":-123.068927,"median":112.199476,"eighty":242.382255,"marketCap":15911927491},{"date":"2024-05-10","current":75.524945,"twenty":-121.619256,"median":112.199476,"eighty":242.382255,"marketCap":15516977501},{"date":"2024-05-17","current":71.135034,"twenty":-119.850332,"median":112.199476,"eighty":242.382255,"marketCap":14615048436},{"date":"2024-05-24","current":70.146149,"twenty":-118.560287,"median":112.199476,"eighty":242.382255,"marketCap":14411877047},{"date":"2024-05-31","current":68.833797,"twenty":-117.48525,"median":112.199476,"eighty":242.382255,"marketCap":14142247727},{"date":"2024-06-07","current":74.720898,"twenty":-116.644766,"median":112.199476,"eighty":242.382255,"marketCap":15351782072},{"date":"2024-06-14","current":77.853908,"twenty":-111.266324,"median":112.294622,"eighty":242.432813,"marketCap":15995474604},{"date":"2024-06-21","current":78.288278,"twenty":-109.731954,"median":112.389767,"eighty":242.575773,"marketCap":16084718112},{"date":"2024-06-28","current":77.170006,"twenty":-106.985723,"median":112.453746,"eighty":243.004654,"marketCap":15854963550},{"date":"2024-07-05","current":74.836422,"twenty":-105.324301,"median":112.453746,"eighty":243.004654,"marketCap":15375517047},{"date":"2024-07-12","current":77.548924,"twenty":15.962481,"median":112.453746,"eighty":243.004654,"marketCap":15932814269},{"date":"2024-07-15","current":78.574777,"twenty":15.978924,"median":112.453746,"eighty":243.004654,"marketCap":16143580851},{"date":"2024-08-02","current":78.205101,"twenty":16.215911,"median":112.851011,"eighty":244.594819,"marketCap":16067628929},{"date":"2024-08-09","current":65.219671,"twenty":16.277249,"median":112.851011,"eighty":244.594819,"marketCap":16734650053},{"date":"2024-08-16","current":66.1694,"twenty":16.362887,"median":112.851011,"eighty":244.594819,"marketCap":16978340065},{"date":"2024-08-23","current":66.792659,"twenty":16.42422,"median":112.851011,"eighty":244.594819,"marketCap":17138261636},{"date":"2024-08-30","current":67.794327,"twenty":16.45237,"median":112.851011,"eighty":244.594819,"marketCap":17395278446},{"date":"2024-09-06","current":63.156978,"twenty":16.479702,"median":112.851011,"eighty":244.594819,"marketCap":16205385808},{"date":"2024-09-13","current":62.607916,"twenty":16.537344,"median":112.851011,"eighty":244.594819,"marketCap":16064502520},{"date":"2024-09-20","current":52.98449,"twenty":16.577992,"median":112.851011,"eighty":244.594819,"marketCap":13595237319},{"date":"2024-09-27","current":52.116378,"twenty":16.619251,"median":112.851011,"eighty":244.594819,"marketCap":13372489417},{"date":"2024-10-04","current":50.573069,"twenty":16.6558,"median":112.851011,"eighty":244.594819,"marketCap":12976493147},{"date":"2024-10-11","current":51.827008,"twenty":16.697708,"median":112.851011,"eighty":244.594819,"marketCap":13298240116},{"date":"2024-10-18","current":51.545057,"twenty":16.760117,"median":112.851011,"eighty":244.594819,"marketCap":13225894644},{"date":"2024-10-25","current":52.227675,"twenty":16.799788,"median":112.851011,"eighty":244.594819,"marketCap":13401046840},{"date":"2024-10-31","current":39.424418,"twenty":16.832825,"median":112.851011,"eighty":244.594819,"marketCap":12706135252},{"date":"2024-11-08","current":39.584187,"twenty":16.900012,"median":112.851577,"eighty":244.597655,"marketCap":12757627091},{"date":"2024-11-15","current":38.791793,"twenty":16.930391,"median":112.851577,"eighty":244.597655,"marketCap":12502245849},{"date":"2024-11-22","current":37.520416,"twenty":16.956385,"median":112.851577,"eighty":244.597655,"marketCap":12092492365},{"date":"2024-11-29","current":39.046069,"twenty":16.983395,"median":112.851577,"eighty":244.597655,"marketCap":12584196546},{"date":"2024-12-06","current":39.122943,"twenty":17.042364,"median":112.851577,"eighty":244.597655,"marketCap":12608972338},{"date":"2024-12-13","current":39.182077,"twenty":17.063524,"median":112.851577,"eighty":244.597655,"marketCap":12628030640},{"date":"2024-12-20","current":38.43699,"twenty":17.120949,"median":112.851577,"eighty":244.597655,"marketCap":12387896040},{"date":"2024-12-27","current":39.631494,"twenty":17.201205,"median":112.851577,"eighty":244.597655,"marketCap":12772873732},{"date":"2025-01-03","current":39.318084,"twenty":17.236838,"median":112.851577,"eighty":244.597655,"marketCap":12671864733},{"date":"2025-01-10","current":40.435714,"twenty":17.313842,"median":112.852143,"eighty":244.60049,"marketCap":13032066634},{"date":"2025-01-17","current":36.219472,"twenty":17.376382,"median":112.852143,"eighty":244.60049,"marketCap":11673209730},{"date":"2025-01-24","current":36.77533,"twenty":17.466817,"median":112.852143,"eighty":244.60049,"marketCap":11852357765},{"date":"2025-01-31","current":37.774691,"twenty":17.638541,"median":112.852143,"eighty":244.60049,"marketCap":12174443062},{"date":"2025-02-07","current":38.046707,"twenty":17.688324,"median":112.852143,"eighty":244.60049,"marketCap":12262111249},{"date":"2025-02-14","current":38.094014,"twenty":17.743365,"median":112.852143,"eighty":244.60049,"marketCap":12277357890},{"date":"2025-02-21","current":30.715125,"twenty":17.776197,"median":112.852143,"eighty":244.60049,"marketCap":13111027516},{"date":"2025-02-28","current":30.891957,"twenty":17.826301,"median":112.852143,"eighty":244.60049,"marketCap":13186509834},{"date":"2025-03-07","current":31.826045,"twenty":17.900998,"median":112.870795,"eighty":244.603325,"marketCap":13585233872},{"date":"2025-03-14","current":31.553417,"twenty":18.033156,"median":112.870795,"eighty":244.603325,"marketCap":13468859871},{"date":"2025-03-21","current":32.000349,"twenty":18.097039,"median":112.870795,"eighty":244.603325,"marketCap":13659636923},{"date":"2025-03-28","current":32.550076,"twenty":18.156695,"median":112.870795,"eighty":244.603325,"marketCap":13894292697},{"date":"2025-04-04","current":30.158988,"twenty":18.272189,"median":112.870795,"eighty":244.603325,"marketCap":12873635468},{"date":"2025-04-11","current":25.171224,"twenty":18.291457,"median":112.852143,"eighty":244.60049,"marketCap":10744563568},{"date":"2025-04-17","current":26.423199,"twenty":18.323094,"median":112.852143,"eighty":244.60049,"marketCap":11278980279}],"updateTime":1745143816494}}}